Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group is currently navigating through a transition year, which has been impacted by recent Medicare wound reimbursement changes and the need for pre-authorization in certain states. However, the company has implemented cost reduction programs to prioritize growth opportunities and streamline operations, which is expected to significantly improve its margin profile. While there are some short-term challenges, the company's strong product portfolio, leadership in the market, and evidence of economic benefits make it a compelling investment opportunity in the long run.

Bears say

MiMedx Group is facing a unique and complex reimbursement situation in its key market, causing a negative impact on its stock performance. Despite potential improvements in the future, such as management's expectation of sequential improvements throughout the year and cost savings from restructuring initiatives, the company is still facing challenges in its pricing and reimbursement. Additionally, while MiMedx has a strong track record and relationships, the recent restructuring and cost reduction initiatives, as well as the CEO's salary reduction, suggest some underlying issues within the company that may continue to affect its stock outlook.

MiMedx Group (MDXG) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 5 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.